Podcasts about Reimbursement

If you're planning to export your MedTech product to Europe, how do you decide which countries you should actually enter first?This doesn't assume they're making a mistake. It poses the central decision the episode helps them make.Europe may look like one export opportunity on a map, but the commercial reality can be very different from country to country. Reimbursement, clinician adoption, buying pathways, language, culture and routes to market can all change as you cross a border. In this episode, Hakeem speaks with Laurent Laffineur, founder of Prime MedTech, about how to build a European go-to-market strategy, prioritise the right export markets and start commercial preparation before you're ready to launch. On todays episode you'll discover:How to prioritise European export markets based on the factors that matter for your specific MedTech product rather than simply choosing the biggest countries. Why reimbursement, KOL support, clinician adoption, language, culture and available budget can dramatically change where your best European opportunities are.Why your European commercialisation and go-to-market work should begin during the regulatory process rather than waiting until you've received EU MDR approval and want to launch immediately. Listen now to learn how to choose the right European export markets for your MedTech product and build your go-to-market strategy before committing significant time and money to launch.Book a 30min Healthcare Export Accelerator discovery callMessage me via DM on LinkedinThis podcast is for clinicians and solo founders feeling stuck in turning their medical devices into real businesses, with practical insight on go to market strategy, sales strategy, product launch, sales plans, business growth, exporting, selling internationally and how to scale up their international sales in MedTech.

In this episode, Ayesha and Andrew discuss the September 16, 2026 issue of JBJS, along with an added dose of entertainment and pop culture. Listen at the gym, on your commute, or whenever your case is on hold! Link: JBJS website: https://jbjs.org/issue.php Sponsor: This episode is brought to you by JBJS Clinical Classroom. Subspecialties: Knee, Spine, Hip, Oncology, Infection, Basic Science, Orthopaedic Essentials, Trauma, Pain Management Chapters (00:00:02) - Intro and Episode Overview(00:01:28) - Table of Contents Headlines(00:02:28) - SI Joint Fusion Sham Trial Overview(00:05:31) - Sham Surgery Design and Crossover Issues(00:07:29) - Outcomes and Statistical Interpretation(00:10:26) - Critique of SI Fusion Trial Conclusions(00:14:30) - Osteosarcoma Machine Learning Prediction Study(00:16:04) - Study Methodology and Data Sets(00:19:37) - Model Performance Results(00:21:24) - Critique of Machine Learning Study Limitations(00:26:26) - Surgeon Communication Burden Study Intro(00:28:25) - Touchpoint Study Methods and Data(00:30:17) - Touchpoint Increase Findings(00:32:20) - Discussion on Resource Allocation Implications(00:34:46) - Historical Perspective on Patient Communication(00:37:59) - Reimbursement and Policy Reflections(00:42:08) - MCL and PCL Avulsion Fracture Study(00:43:16) - Vertebral Body Tethering Outcomes Study(00:45:39) - Closing Remarks

In this episode, Courtney McNamee, Director, Revenue Cycle and Reimbursement, Altru Health System, discusses building a more proactive, patient-centered and data-driven revenue cycle while responding to payer pressure, reimbursement changes and the growing role of AI and automation. She also shares how Altru is preparing for thoughtful growth across rural communities and strengthening the patient financial experience.

Send us Fan Mail2027 is not one reimbursement change. It's multiple changes moving at different speeds, some proposed, some confirmed, and the most expensive mistake is treating all of them like the same fee-schedule cut. Change 1, Medicare rates: CMS has proposed two 2027 conversion factors. The headline percentage is never your practice's percentage. Model your own top codes. Change 2, global procedures: Same-day E/M billed with a global procedure is getting more scrutiny. Documentation, not billing habit, decides whether it survives an audit. Change 3, specialty codes: New 2027 OB/GYN coding replaces the bundled global obstetric payment. The pattern applies to every specialty as codes get more specific. Change 4, digital care: Remote monitoring reimbursement is becoming more conditional on established-patient status, a documented initiating visit, and employed clinical staff. Change 5, rate transparency: Federal transparency files make commercial negotiated rates newly accessible, setting up next episode's data methodology. Three actions this week: Pull your top 20 Medicare CPT codes by allowed dollars Check whether your practice bills E/M on the same day as global procedures, and audit the documentation If you run remote monitoring, confirm employed clinical staff and a documented initiating visit Episode breakdown 00:00 Hook 00:40 The 2027 reframe 03:00 Change 1: Medicare rate nuance 07:00 Change 2: Global procedure scrutiny 11:00 Change 3: OB/GYN as the specialty example 15:00 Change 4: Digital care conditions 18:00 Change 5: Rate transparency 20:00 The three-question diagnostic 23:00 Close and next episode Resources 2027 Revenue Impact Brief: eligibility.natrevmd.com/know-where-2027-will-impact-your-practices-revenue-free-brief-natrevmd Metrics Audit Review (free, physician-led): eligibility.natrevmd.com/metrics-audit-natrevmd Website: natrevmd.com Referenced: EP210, the Modifier 25 framework Coming next: EP214, the one number to know before you negotiate with a payer 

Dr. Jason Crowell and Ka-Ho Wong discuss national trends in Medicare reimbursement for inpatient neurologic care.  Show citation:  Wong KH, Castillo M, King J, et al. National Trends in Medicare Charges and Reimbursement for Inpatient Neurologic Care, 2013-2023. Neurology. 2026;107(6):e218460. doi:10.1212/WNL.0000000000218460 

Join us as we sit down with Quentin Blackford, CEO of iRhythm Technologies, for an exclusive conversation that dives deep into the seismic shifts reshaping cardiac monitoring.

Dr. Jason Crowell talks with Ka-Ho Wong about national trends in Medicare reimbursement for inpatient neurologic care, including the widening gap between hospital charges and payments and its implications for healthcare policy.  Read the related article in Neurology®. Disclosures can be found at Neurology.org. 

In this episode of Medsider Radio, we sat down with Deanna Harshbarger, CEO of Cala Health.Cala Health developed the Cala kIQ® System, a prescription wearable therapy for action hand tremor.Deanna holds a degree in chemical engineering and brings more than 20 years of commercial medtech experience to Cala. Before joining the company, she held senior leadership roles at Johnson & Johnson, Boston Scientific, and Medtronic, and helped develop and commercialize technologies across interventional cardiology, neuromodulation, and diabetes care.In this conversation, Deanna shares how she empowers leadership teams to execute, building clinical evidence step-by-step, how patient observation shapes product development, and why raising capital is both a sprint and a marathon.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Deanna Harshbarger, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:34) - Deanna's journey from J&J, Boston Scientific, and Medtronic to Cala Health (08:16) - How Cala personalized therapy around each patient's unique experience (11:53) - Operating lessons Deanna carried from strategics to startups (22:27) - The unboxing interview that changed Cala's product design (29:16) - How Cala balanced feasibility studies, RCTs, and real-world evidence after its commercial launch (34:33) - Years of clinical evidence helped Cala win reimbursement for a new therapy (38:52) - The case for holding back when you're ready to commercialize (44:30) - Why fundraising is both a sprint and a marathon

Food as Medicine: Why Medical Nutrition Therapy and Medically Tailored Meals Belong in Modern Healthcare: Registered dietitian nutritionist Leyla Muedin argues that food should be treated with the same rigor as medication through medical nutrition therapy (MNT) and “diet prescriptions,” integrating nutrition into treatment plans rather than leaving it as optional advice. She cites evidence that medically tailored meals (MTMs) can improve outcomes and reduce costs, including a Health Affairs simulation estimating $23.7B in first-year net savings nationwide and a Nature Medicine analysis of a Massachusetts Medicaid demonstration (2020–2023) showing MTM recipients had 31% fewer hospitalizations, 20% fewer emergency visits, and $3,433 lower total healthcare costs, offsetting 98% of program costs. She discusses food insecurity, expanding Medicaid coverage via Section 1115 waivers, EHR integration, and how MTMs support adherence for conditions such as diabetes, cardiovascular disease, chronic kidney disease, depression, and IBS (including low FODMAP).

What happens when AI, real-time healthcare data, and advanced analytics are used to transform the chiropractic profession?In this episode of TechTalk Healthcare, Dr. Jay Greenstein sits down with Brad Cost, CEO of InfinEDI, to explore the evolution of chiropractic technology, healthcare data, reimbursement analytics, and the future of evidence-based chiropractic care.Brad shares the remarkable origin story of InfinEDI—from purchasing the company for just $7,000 to building a technology and analytics platform that now processes an enormous volume of chiropractic claims. The conversation also explores how years of accumulated claims data are being transformed into powerful analytics and a new data lake designed to give researchers access to fresh, real-world chiropractic data. Brad and Jay discuss how AI could dramatically accelerate chiropractic research by allowing researchers to query massive datasets and perform statistical analyses in minutes rather than the months or years traditionally required. They explain why real-world data could help generate stronger evidence around chiropractic safety, effectiveness, and cost-effectiveness. The episode also dives into healthcare reimbursement, data ownership, value-based care, AI-powered claims processing, and the growing role of data in shaping the future of chiropractic policy and advocacy.In this episode:AI and healthcare data analyticsThe future of chiropractic researchReal-time chiropractic data and researchHealthcare reimbursement analyticsAI-powered claims processingValue-based healthcareChiropractic advocacy and healthcare policyProving chiropractic safety and effectivenessThe future of evidence-based chiropractic careBuilding a data-enabled chiropractic professionFor chiropractors, researchers, healthcare entrepreneurs, and anyone interested in AI and the future of healthcare, this episode offers a fascinating look at how data could change the profession.

If you sell on Amazon, there's a chance you're missing out on money without even realising it.Lost inventory, invoice discrepancies, overbilling and fulfilment issues can all add up over time, but many sellers never spot them, let alone know they can claim the money back.In this week's episode, I'm joined by Liam from Threecolts to talk about Amazon reimbursement claims, how they work, what Amazon sellers should be checking, and why recovering lost revenue doesn't have to become another job on your to do list.We also explore marketplace expansion and how brands can grow onto platforms such as TikTok Shop, Temu and Walmart without creating unnecessary manual work.Whether you're an established Amazon seller or you're starting to think about expanding beyond your own website, this episode is packed with practical advice to help you make informed decisions and protect your profitability.Find Liam and the team here:Website: threecolts.comInstagram : threecolts_comLinkedin: https://www.linkedin.com/company/threecolts/posts/?feedView=allLET'S CONNECTFollow me on YouTubeFind me on InstagramWork with me Buy My Book: Bring Your Product Idea To LifeIf you enjoy this podcast, and you'd like to leave a tip, you can do so here: https://bring-your-product-idea.captivate.fm/supportMentioned in this episode:Amazon Made Easy is now openMy membership, Amazon Made Easy is now open. It's a membership for people who are selling on Amazon (or planning to) and want regular access to support, somewhere to ask questions and talk things through, and a bit of structure and accountability as they grow. Inside, there are live Q&A calls, optional co-working sessions and a small, supportive community. Find out more: https://vickiweinberg.com/membership membership

Hospitals are now in joint ventures with physicians groups for ASCs, something unthinkable 20 years ago, says Erik Tellefson, senior managing director, head of Healthcare Real Estate Lending at Capital One.

In this episode of Medsider Radio, we sat down with Michael Mangano, President and CEO of ABK Biomedical. ABK's Eye90 is an investigational Y90 radioembolization device for treating unresectable liver cancer.Michael brings over 30 years of medical device experience, including 15 years at Boston Scientific in commercial and international leadership roles. He previously served as CEO of ReShape Medical and as President of the Americas for Sirtex Medical, scaling regional revenues from $34 million to over $130 million.In this interview, Michael discusses the thinking behind ABK's pivot into Y-90 radioembolization, what it takes to execute a 120-patient pivotal trial while retaining ownership over the clinical function, how to build capabilities that competitors can't quickly catch up to, and why the player-coach culture gives startups an execution advantage.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Michael Mangano, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:09) - Michael's journey from Boston Scientific and Sirtex to leading ABK Biomedical (04:54) - Why Michael pivoted ABK from embolization to radioembolization as soon as he joined as CEO (09:24) - How ABK reimagined Y-90 around physician control and patient-specific dosing (21:08) - What a functioning player-coach culture looks like inside a startup (27:26) - Lessons learned from a complex 120-person pivotal trial and how ABK remained the face of the study while partnering with a CRO (37:13) - How ABK is building advantages competitors can't easily replicate (42:50) - Michael's framework for choosing the right investors

The HSE has approved the reimbursement of the drug Skyclarys for people with Friedreich's Ataxia.This comes following a substantially improved financial offer by drug firm Biogen to the Health Service Executive.Joining Ciara to discuss this is Minister for Health, Jennifer Carroll MacNeill.

Psychiatrists in Montana say a major insurance company is shortchanging them through a practice called “downcoding.” Psychiatric associations have filed two complaints with state regulators.

Gov. Spanberger has said there isn't enough money to reimburse cities and counties for the redistricting special election.

SLPs have been screaming for a long time that reimbursement is too low, costs are rising, and access to speech-language pathology services is being threatened. But can we prove it with national data?In this episode, Jeanette Benigas, PhD/SLP, introduces The Speech Pathology Education, Advocacy and Knowledge (SPEAK) Project and its first major initiative: building a national economic dataset that shows what it actually costs to provide SLP services and turn those numbers into credible national evidence we can use to advocate directly with CMS during the current public comment period.Jeanette is joined by private practice owner Holly Ellis, MS/SLP, and CPA Cody Underwood to discuss how North Carolina built its own cost analysis, why independent financial analysis matters, and what the national SPEAK Project will measure, including CPT 92507, dysphagia and cognitive services, treatment time, payer mix, Medicare and Medicaid reimbursement, workforce pressures, waitlists, and access to care.The immediate goal: collect high-quality data from all 50 states (+ DC) and turn that evidence into meaningful advocacy.Give data. Give dollars. Or do both.Everything starts at speakproject.net.Get caught up, wherever you stream podcasts!#110: CPT 92507 Is Being Deleted? What Every SLP Must Know About the New Speech Therapy Codes#111: CPT 92507 Q&A for SLPs: Your Questions Answered#113: CPT 92507 Option B: This Is Our Week to Advocate#115: CMS's NEW Pediatric G Code Explained: What Every SLP Needs to Know#116: What the New Speech Therapy Codes Mean for Adult SLPs#117: The End of CPT 92507: Is Your SLP Documentation Ready?✨ Grateful to Chomper Champs for bringing so much positivity and fun to the pediatric SLP space. Follow the link to order the

Today - Cochise County Sheriff Mark Dannels says Arizona’s southern border is now “manageable,” as state and local officials seek more than 902 million dollars in federal reimbursement for years of border-security spending.Support the show: https://www.myheraldreview.com/site/forms/subscription_services/See omnystudio.com/listener for privacy information.

Today - Cochise County Sheriff Mark Dannels says Arizona’s southern border is now “manageable,” as state and local officials seek more than 902 million dollars in federal reimbursement for years of border-security spending.Support the show: https://www.myheraldreview.com/site/forms/subscription_services/See omnystudio.com/listener for privacy information.

In this episode of Medsider Radio, we sat down with we sat down with Murthy Simhambhatla, CEO of SetPoint Medical.SetPoint is commercializing the first FDA-approved neuroimmune modulation implant for rheumatoid arthritis.Previously, Murthy was CEO of Evolus, leading the company through its IPO, and held multiple leadership roles at Abbott, including President of Abbott Medical Optics and head of the company's Ibis Biosciences molecular diagnostics business. Earlier in his career, Murthy led development of Abbott's XIENCE drug-eluting stent platform following Abbott's acquisition of Guidant. Murthy holds a Ph.D. in Polymer Engineering and is a Fellow of the American Institute for Medical and Biological Engineering.In this interview, Murthy discusses building commercial conviction years before launch, how to sequence platform indications around adjacent markets, and why SetPoint built its reimbursement function in-house rather than outsourcing it.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Murthy Simhambhatla, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:18) - Murthy's journey from Guidant, Abbott, and Evolus to leading SetPoint Medical (09:53) - How SetPoint stimulates the vagus nerve to reprogram the immune system (11:32) - Why SetPoint built a reimbursement hub around the entire referral workflow (21:36) - A guide to building technical and commercial conviction for a novel therapy (26:58) - The trifecta Murthy wanted in place before commercial launch (30:56) - Why rheumatoid arthritis became SetPoint's first indication (36:11) - How commercial adjacency shapes platform expansion (42:20) - A business case for handholding patients through reimbursement (48:03) - The two lessons behind every skeptical investor question

This episode of PT Breakfast Club starts with Jimmy McKay reporting from Prompt HQ after a trip to Portland for APTA's Payment Summit and House of Delegates.Jimmy explains how he got in trouble for live tweeting the House of Delegates, why he likes the word “payment” more than “reimbursement,” and what it felt like watching the profession debate policy language in real time.Dave Kittle pushes hard on the bigger question: has payment advocacy actually moved the needle for physical therapy? If insurance companies and Medicare are not meaningfully increasing payment, should more PTs stop waiting and build direct-to-consumer cash-pay offers?Tony Maritato adds the counterpoint: maybe some advocacy success is measured by slowing the decline, not producing giant wins.Then the show turns into a business strategy clinic thanks to Grandpa the Mailbox Guy.For $320, he solves the whole mailbox problem. No hourly rate. No overexplaining. No “here are the 17 steps.” Just a clear result at a clear price.The crew applies that lesson to PT, including grab bar installation, home safety consults, cash-pay evaluations, AI content ideas, therapist recruiting, viral video formats, and what practices should do when a clinician calls out sick.The takeaway: keep it stunningly simple. The customer does not want your process. They want the problem solved.

South Africa says it is asking Nigeria, Malawi and Ethiopia to share the cost of deporting tens of thousands of illegal immigrants to their home countries. The country's Department of Home Affairs says it spent nearly $18 million in the exercise, far exceeding the budgetary allocation. About 82,000 people were repatriated to their home countries since anti-migrant protests started. And a UN report says one in three people can't afford a healthy diet, despite a decline in global hunger in recent years. How are families across Africa coping with the affordability crisis?Presenter: Nkechi Ogbonna Producers: Basma El Atti, Keikantse Shumba and Ayuba Iliya Senior Producer: Charles Gitonga Technical Producer: David Kinyanjui Editors: Rhoda Odhiambo and Maryam Abdalla

MB2's Chief Revenue Officer Clint Ellenberg is back for another round to discuss what's happening with insurance right now and how dentists can ensure they're actually getting paid what they deserve.  Clint shares what he's seeing across the dental space, from reimbursement challenges to shifting views on in-network participation. We discuss how insurance affects practice profitability, why some dentists are reconsidering their approach, and practical steps to make more informed decisions. ------------------------------------------------------------------------  Subscribe & Listen: Spotify: https://open.spotify.com/show/69Dz26hgC9D6YqwN8JMDBV Apple Podcast: https://podcasts.apple.com/us/podcast/mb2-underground/id1747349567 ---------------------------------------------------------------------- Follow MB2 Dental on Social: MB2 Dental: mb2dental.com Instagram: instagram.com/mb2dental Facebook: facebook.com/mb2dental YouTube: youtube.com/@mb2dental LinkedIn: linkedin.com/mb2-dental

Catch Up on the latest leading news stories around the country with Mandy Wiener on Midday Report from 12:00 to 13:00. The Midday Report with Mandy Wiener is 702 and CapeTalk’s flagship news show, your hour of essential news radio. The show is podcasted every weekday, allowing you to catch up with a 60-minute weekday wrap of the day's main news. It's packed with fast-paced interviews with the day’s newsmakers, as well as those who can make sense of the news and explain what's happening in your world. All the interviews are podcasted for you to catch up and listen to. Thank you for listening to this podcast of The Midday Report Listen live on weekdays between 12:00 and 13:00 (SA Time) to The Midday Report broadcast on 702 https://buff.ly/gk3y0Kj and on CapeTalk https://buff.ly/NnFM3Nk For more from The Midday Report go to https://buff.ly/BTGmL9H and find all the catch-up podcasts here https://buff.ly/LcbDdFI Subscribe to the 702 and CapeTalk daily and weekly newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk See omnystudio.com/listener for privacy information.

The Midday Report with Mandy Wiener is 702 and CapeTalk’s flagship news show, your hour of essential news radio. The show is podcasted every weekday, allowing you to catch up with a 60-minute weekday wrap of the day's main news. It's packed with fast-paced interviews with the day’s newsmakers, as well as those who can make sense of the news and explain what's happening in your world. All the interviews are podcasted for you to catch up and listen to. Thank you for listening to this podcast of The Midday Report Listen live on weekdays between 12:00 and 13:00 (SA Time) to The Midday Report broadcast on 702 https://buff.ly/gk3y0Kj and on CapeTalk https://buff.ly/NnFM3Nk For more from The Midday Report go to https://buff.ly/BTGmL9H and find all the catch-up podcasts here https://buff.ly/LcbDdFI Subscribe to the 702 and CapeTalk daily and weekly newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567See omnystudio.com/listener for privacy information.

Show recorded on 27/7/26 Released 10/8/26 58 minutes In which we read through some correspondence and find out how things are going with the booking service and getting reimbursements for tests cancelled by the DVSA. Correspondence Test Waiting Times Traffic Light Fun Six Service Wait Reporting Booking Service Misuse Cancellation Fee Costs Links Report Abuse of Booking System

Reimbursement keeps shrinking — but your profit doesn't have to. In this episode, Shaun Kirk breaks down why most practice owners don't actually have a marketing problem, they have an operations problem, and shows exactly where the money is quietly leaking out of your clinic.Drawing on his experience as a private practice consultant and separately running 180+ locations as a VP of Operations in private equity, he walks through:The "leaky bucket" — why roughly 50% of your caseload is already past patients, and what that means for your true patient lifetime valueThe five places profit disappears: front desk control, clinician execution, patient experience, billing/coding, and systemsWhy "2 to 3 times a week" isn't a real plan of care until your team can actually hold that line — and how to fix itThe cluster-booking trick that changes how busy (and profitable) your schedule feelsA real example of adding just $7 per visit in average reimbursement — and what it took operationally to get thereIf you've been telling yourself "we just need more new patients," this episode might change your mind — and show you where the real leaks are hiding.Ready to find your own leaks and fix them for good? Shaun's 6-Week Practice Accelerator is a live, guided program where he personally analyzes your practice, finds where revenue is slipping through the cracks, and builds a week-by-week plan to plug it.

In this episode, host Dr. Nick Rainey is joined by Dr. Bremen Abuhl and Dr. Dallas Ehrmantraut to discuss their 2025 Physical Therapy Journal article, “First Contact Physical Therapy Compared to Usual Primary Care for Musculoskeletal Disorders: A Systematic Review and Meta-Analysis of RCTs.”The conversation explores whether physical therapists should serve as the first point of contact for patients with musculoskeletal disorders and how first contact PT compares with usual primary care.Dr. Abuhl and Dr. Ehrmantraut discuss their findings, including reduced imaging utilization, reduced prescription medication utilization, and similar clinical outcomes for pain, disability, and health-related quality of life. They also unpack the terminology around direct access, first contact PT, and primary care PT, and explain why direct triage models may offer a more efficient pathway for patients.The episode also addresses real-world implementation barriers, including reimbursement models, state scope-of-practice variation, imaging privileges, medication prescribing, stakeholder buy-in, and the need for PTs to step confidently into first contact roles.Key TakeawaysFirst contact PT is not the same as direct access. Direct access means patients can choose PT without referral. First contact PT means the PT is the first provider evaluating the patient for that episode of care.The study found lower healthcare utilization. First contact PT was associated with 45% less imaging and 71% less prescription medication utilization compared with usual primary care.Clinical outcomes were similar. Pain, disability, and health-related quality of life outcomes were statistically similar between first contact PT and usual primary care.Less imaging is not automatically the goal. The more important question is appropriate utilization: avoiding both overuse and underuse.Implementation is a system problem. Scope of practice, reimbursement, stakeholder buy-in, state law, and health system workflows all influence whether first contact PT can work.Direct triage may be the stronger model. Compared with warm handoffs, direct triage allows patients with appropriate MSK presentations to start with PT as the first provider.PTs need to be ready for real-world first contact care. That includes identifying red flags, determining urgency, ordering or recommending imaging when appropriate, and referring to the right provider when needed. Chapters: 00:00 — Welcome and guest introductions 01:17 — Dr. Bremen Abuhl's path into first contact PT research 03:13 — Dr. Dallas Ehrmantraut's clinical spark for the topic 06:16 — Overview of the PTJ systematic review and meta-analysis 09:52 — Direct access vs first contact PT vs primary care PT 13:15 — Global evidence and limited U.S.-based RCTs 16:24 — Imaging findings and appropriate utilization 20:37 — Medication utilization findings 23:27 — Clinical outcomes: pain, disability, and quality of life 25:20 — Study limitations and downstream utilization 27:13 — Why longer-term outcomes matter 31:15 — Risk of bias and crossover between groups 33:36 — U.S. system barriers to first contact PT 36:37 — Reimbursement, payer models, and stakeholder concerns 40:45 — Direct triage vs warm handoff models 44:15 — Scope of practice and state-level barriers 46:08 — Real-world safety, red flags, and PT decision-making 48:01 — Call to action for physical therapists 50:06 — Closing thoughts

In this episode of Medsider Radio, we sat down with David Veino, President and CEO of Neuros Medical.Neuros is commercializing the FDA-approved Altius Direct Electrical Nerve Stimulation System for chronic post-amputation pain.Before Neuros, David held senior commercial leadership roles at Cardiovascular Systems (CSI) and Stryker, and helped grow CSI's coronary and peripheral business from approximately $50 million to more than $250 million in annual revenue while leading key amputation-prevention initiatives. He also serves as a private equity advisor with Sectoral Asset Management. In this interview, David discusses how commercialization begins by mapping the patient journey upstream, what it takes to generate gold-standard clinical evidence for a novel therapy, how investors assess scalable medtech businesses, and how to build an investor pitch that earns the next meeting.  Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with David Veino, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:02) - David's 30-year medtech journey from cardiovascular devices to leading Neuros (04:38) - How Neuros is treating chronic post-amputation pain with on-demand neuromodulation (11:08) - Why Neuros completely changed its strategy halfway through the pivotal trial (15:36) - Why commercialization starts with referral pathways, not end-users (18:09) - How prosthetists became one of Neuros' most important referral sources (26:11) - What it takes to generate gold-standard clinical evidence for a first-of-its-kind therapy (37:41) - Building an investor pitch that earns the next meeting (41:42) - What gets David excited enough to invest in a medtech company

Host: Maria Berrocal How much money are retina surgeons losing on secondary IOL procedures? In this episode of Clinical Minute: Retina, host Maria Berrocal, MD, speaks with Nimesh "Nemo" Patel, MD, whose research uncovered how many cases are unprofitable under current Medicare reimbursement rates, and assess how much cash surgeons burn per case. Dr. Patel discusses the implications for patient access, the advocacy efforts underway through the ASRS Health Economics Committee, and why closing the gap between reimbursement and operative complexity will require direct engagement with policymakers.

In this episode of Medsider Radio, we sat down with Vijit Sabnis, co-founder and CEO of Adaptyx Biosciences.Adaptyx is a Stanford spinout developing wearable technology for continuous molecular monitoring.Over the past 20 years, Vijit has worked at the intersection of deep technology as an inventor, founder, and investor. Before Adaptyx, he was a Partner at Khosla Ventures and co-founded Solar Junction to commercialize high-efficiency solar cell technology. He holds a Ph.D. in Electrical Engineering from Stanford.In this interview, Vijit discusses how to recognize when a scientific idea is worth building a company around, how to build startup-style learning cycles when spinning technology out of academia, and designing products that are easy for clinicians and consumers to adopt. Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Vijit Sabnis, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:17) - Vijit's path from Stanford, solar energy, and venture capital to building Adaptyx (07:25) - How Adaptyx is trying to do for hormones what continuous glucose monitors did for diabetes (13:50) - The signals Vijit looked for before founding Adaptyx (25:35) - How Adaptyx turned academic research into startup-speed learning cycles (32:15) - Why cortisol became the company's first clinical application (36:26) - How Adaptyx is designing new molecular data to fit existing clinical workflows (42:12) - Why new consumer health platforms opened new paths to commercialization (47:24) - Fundraising in an era of shorter attention spans

Jim and Chris discuss listener emails on Social Security survivor benefit strategies, a Roth 401(k) catch-up rule loophole, HSA reimbursement for Medicare premiums, pension options including a lump sum rollover, and trust titling versus individual beneficiaries. (13:00) — George asks whether his brother can claim his own Social Security benefit at 62 and switch to the higher survivor benefit at full retirement age. (22:45) — A listener asks whether starting a new job in 2026 could exempt him from the new mandatory Roth 401(k) catch-up rule. (28:45) — The guys field a question about using HSA funds to reimburse Medicare Part A premiums paid for a spouse before age 65. (40:00) — Jim and Chris review a listener’s decision to take a pension lump sum and roll it into an IRA over the annuity options. (1:13:00) — Georgette asks which accounts should be retitled into her trust versus left as individual beneficiary designations. The post Social Security, Roth 401k, HSA Reimbursement, Pension Options, Trust Planning: Q&A #2630 appeared first on The Retirement and IRA Show.

In this episode of The Med-Tech Talent Lab, Mitch Robbins sits down with Spencer Bailey, Vice President of Market Access and Reimbursement at SetPoint Medical, to discuss one of the most critical yet often overlooked aspects of MedTech commercialization: market access.Spencer has built his career at the intersection of healthcare finance, reimbursement, and MedTech innovation. After beginning on the provider side of healthcare and later advising organizations as a healthcare consultant, he transitioned into the medical device industry, where he has helped companies develop reimbursement strategies that support successful commercialization. Today, he leads Market Access and Reimbursement at SetPoint Medical and recently helped secure CMS Transitional Pass-Through Payment for the company's breakthrough technology. SetPoint Medical is pioneering a new approach to treating rheumatoid arthritis with an FDA-approved implantable neuromodulation system that stimulates the vagus nerve to activate the body's natural anti-inflammatory pathways. The therapy represents the first approved neuroimmune modulation treatment for adults with rheumatoid arthritis who have not responded adequately to certain advanced drug therapies.During the conversation, Spencer explains why reimbursement should be viewed as a core business competency instead of an afterthought. He shares how companies can improve their chances of commercial success by bringing market access into the conversation early, often before clinical trials begin. Drawing on his experience across provider organizations, consulting, and MedTech, he offers practical insights on reimbursement strategy, hiring exceptional market access talent, building high-performing teams, and translating complex reimbursement challenges into business strategy.Whether you're a MedTech executive, founder, investor, commercial leader, or reimbursement professional, this episode offers actionable insights on bringing innovative therapies to patients while building a commercialization strategy that lasts.In this episode, you'll learn:• Why market access should be part of product development from day one• When MedTech companies should hire their first market access leader• The biggest misconceptions about reimbursement and commercialization• What separates exceptional market access professionals from the rest• How to build reimbursement teams that create strategic value• Lessons from commercializing a first-of-its-kind medical technology• Where AI will, and will not, change the future of market accessSpencer Bailey on LinkedIn:https://www.linkedin.com/in/spencer-bailey-11ab1410/SetPoint Medical on the web:setpointmedical.com

CMS surprised speech-language pathologists with a proposed pediatric G code, creating new questions about reimbursement, billing, and the future of pediatric speech therapy.In this episode, Jeanette Benigas, PhD/SLP, is joined by billing expert Rick Gawenda and pediatric private practice owner Emily Watkins, MCD/SLP, to break down what the proposed G code actually means, who it applies to, and why it matters far beyond Medicare.Topics include:• Who the proposed pediatric G code applies to• Why commercial insurance and Medicaid may choose different billing paths• Timed CPT codes vs. the proposed G code• How reimbursement could change for pediatric practices• Operational challenges for clinics and business owners• Why giving payers multiple billing options may create inconsistencies• The risks surrounding untimed codes and future payer audits• Why understanding RVUs and practice expense matters• What clinicians and practice owners should consider before submitting comments to CMSWhether you're an employee, private practice owner, school-based SLP, or administrator, these proposed coding changes have the potential to affect your reimbursement, documentation, scheduling, and future practice.This episode is designed to help you understand the proposal, not tell you what position to take, so you can make informed decisions on how to comment before the CMS comment period closes.✨ Grateful to Chomper Champs for bringing so much positivity and fun to the pediatric SLP space. Follow the link to order the

Learn when grantor trusts can reimburse income taxes, key IRS rules, state law differences, and planning strategies for estate planners. The American College of Trust and Estate Counsel, ACTEC, is a professional society of peer-elected trust and estate lawyers in the United States and around the globe. This series offers professionals best practice advice, insights, and commentary on subjects that affect the profession and clients. Learn more in this podcast.

In this episode of Medsider Radio, we sat down with Bob Paulson, President and CEO of Sonex Health. Sonex's UltraGuideCTR device is a minimally invasive technology that enables ultrasound-guided carpal tunnel release procedures to be performed outside the surgical suite using local anesthesia, expanding patient access and reducing the cost of care.Before joining Sonex, Bob led multiple venture-backed medical device companies through commercialization, including NxThera, acquired by Boston Scientific, Restore Medical, acquired by Medtronic, and VentureMed Group. Earlier in his career, he held senior leadership roles at Medtronic, Advanced Bionics, and Endocardial Solutions, which was acquired by St. Jude Medical.In this interview, Bob explains how to build a reimbursement strategy before your first clinical study, drive physician adoption when introducing a new care pathway, and raise capital aligned with value inflection points. Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Bob Paulson, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:19) - Bob's path from Medtronic to multiple medtech exits before joining Sonex (05:38) - Why 80% of eligible carpal tunnel patients avoid surgery — and how Sonex is changing that (11:11) - The reimbursement challenge that reshaped Sonex's clinical evidence strategy (19:07) - Reimbursement is a three-leg process: FDA, CPT, and payer coverage (22:07) - Reverse engineering your company from the exit you're trying to achieve (29:35) - How Sonex helped surgeons move carpal tunnel procedures out of the OR (39:06) - Sonex's "pitcher-catcher" approach to physician and patient adoption (41:59) - Bob's framework for choosing investors who can finance the entire journey, not just the next round

Taylor Swift Today, one week later, with Lyla: the newlyweds have vanished into married life, the wild details are still trickling out, and we finally know how we'll see the dress. A Dior spokesperson confirmed that Taylor Swift herself will share the first official wedding photos on her own Instagram — no date yet, exactly the way she's controlled this story from day one. Plus the first sighting of Taylor since the wedding (a low-key Montana getaway with her new in-laws), the city reimbursement that settled the "who paid" debate, and a few late details that'll make you smile. Here's the week-later check-in.

TODAY ON THE ROBERT SCOTT BELL SHOW: Reimbursement Code Monopoly, Prof. Dr. Dana Flavin, Foundation for Collaborative Medicine and Research, Hydrangea Arborescens, Politicized Science, Dr. Stephanie Haridopolos, HHS Agenda, Health Freedom, Americans Quitting Multivitamins and MORE! https://robertscottbell.com/reimbursement-code-monopoly-prof-dr-dana-flavin-hydrangea-arborescens-politicized-science-dr-stephanie-haridopolos-americans-quitting-multivitamins/ Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

Joe Rodriguez (co-founder, Guide Anesthesia) sits down with Randy Moore (EVP and National Chief CRNA, NorthStar Anesthesia) and Gary Keeling (VP of Anesthesia Services, Coronis RCM). Three seats, three vantage points on the same business. Let the spicy takes flow. First docket: the Arizona reimbursement fight. Gary calls the QZ cut a pure money grab. Randy steelmans the insurer's lobbyist before dismantling him, and explains why the hospitals least prepared to absorb the hit will be the ones paying it. Joe walks through why reimbursement parity doesn't raise costs when subsidies fill the gap, and tells the story of the insurer that paid patients directly for eight years. Second docket: the Texas non-compete case. Gary argues exits should hurt but not kill. Randy says hospitals deserve the right to fire bad vendors, but a $30 million buyout is anti-competitive. Joe draws the line between covenants that trap clinicians and the non-solicit rule that just says don't be shady. Plus: why the resume from Hawaii is a red flag, and what the law of inertia does to anesthesia groups that confuse stability with health. Takeaways: The QZ cut is not a savings. It's a transfer. Hospitals backstop anesthesia economics, so a 15% commercial reimbursement cut flows through subsidies to hospitals and ultimately taxpayers, while insurers book the difference. Reimbursement parity does not raise costs in anesthesia. Compensation sits above reimbursement and subsidies fill the gap, so cutting one payer's rate changes who pays, not how much is paid. The facilities that use QZ most are the ones least able to absorb the cut. Rural and underserved programs run closest to the margin, which makes this bad policy independent of the scope debate. CRNAs can lose non-compete fights. In the Texas case, the new employer contractually agreed to cover legal costs and damages, and the court sided with the original group anyway. A buyout promise is not a shield. The covenant you signed is enforceable as written, and "I read online it's unenforceable" is not a legal strategy. The line is solicitation, not competition. A non-solicit protects the group that gave you access to its surgeons and referrals without trapping you in place. Competing down the street is fair game. Taking the business with you is shady. Switching costs are a strategy. A $30 million buyout stops being protection and becomes a hostage situation. Hospitals should be able to fire bad vendors at a price that hurts but doesn't kill. Sign contracts like you plan airways. Have a plan A, B, and C for your exit before the honeymoon period ends, because the group that looks great at signing may not look great in year three. Want more Dr. Joe Rodriguez? Tik Tok: @jrodcrna21 Instagram: @jrod.crna & @abouttherestpod YouTube: @AboutTheRest Thanks for my co-hosts: Randy Moore (EVP & National Chief CRNA, NorthStar Anesthesia) Gary Keeling (VP of Anesthesia Services, Coronis RCM) To Learn More about Human Content Visit: ⁠⁠⁠http://www.human-content.com⁠⁠⁠ To Learn More about About The Rest Visit: www.abouttherest.com Got a Question? hello@abouttherest.com Part of the Human Content Podcast Network Learn more about your ad choices. Visit megaphone.fm/adchoices

A new CEO steps into The Rose and immediately confronts the realities behind 60,000annual screenings: rural healthcare deserts, under‑reimbursed mammograms, and anaging but essential mobile fleet. During this conversation, COO Jessica Duckworth sits down with Angie Lane to talk aboutwhat surprised her most in her first six weeks, why 3D mammography on five pinkcoaches is non‑negotiable for twenty‑six Texas counties with no freestanding imaging,and how shrinking insurance and Medicare payments make patient navigation andfinancial stewardship core to The Rose’s future. Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts. Key Questions Answered 1. What did Angie learn in her first weeks about serving 60,000 women a year acrossforty‑five counties?2. How do The Rose’s five mobile coaches deliver 3D mammograms in counties with noimaging centers at all?3. Why does Angie describe many of The Rose’s service areas as “healthcare deserts”?4. What does it actually cost The Rose to provide a screening compared to what manyinsurers and Medicare reimburse?5. How does Angie connect her new role to her experience as a working mother who mighthave to lose a day’s work just to reach the medical center?6. Why does she see patient navigation as a uniquely important service for women whoreceive a cancer diagnosis?7. How does Angie’s personal experience hearing a difficult diagnosis about her childshape her empathy for patients at The Rose?8. What financial priorities does Angie name for keeping The Rose stable whilemaintaining high standards of care?9. How does Jessica frame the dual challenge of limited healthcare options and limitedhealth insurance in rural Texas? Timestamped Overview00:00 Jessica welcomes listeners, introduces herself as COO of The Rose, and framesthe episode as a chance for the community to meet new CEO Angie Lane.00:25 Angie thanks Jessica and shares her awe at the scale of The Rose’s work,including serving 60,000 women annually and operating the largest mobilemammography fleet in Texas.00:30 She describes the five RV coaches, their 24‑hour air‑conditioning, bumpy ruralroads, and sophisticated equipment required to bring mammograms to areas withoutfreestanding clinics.01:13 Jessica notes that out of The Rose’s forty‑five‑county service area, twenty‑sixcounties have no freestanding mammography units, making the mobile fleet essential.01:19 She adds that the coaches carry 3D mammography, the gold standard, whichmany local facilities still do not offer.01:33 Angie reflects on growing up near the Texas Medical Center, contrasts thataccess with surrounding counties she now sees as healthcare deserts, and imaginesthe burden on working mothers who would have to take a full day to reach the medicalcenter for routine screening.02:21 Jessica points out that rural communities face deserts in both healthcare servicesand health insurance coverage, compounding access gaps.02:50 Angie explains that providing a mammogram can cost The Rose around $300,while some reimbursements come in around $150–$175, and says closing that gapwithout sacrificing quality is a priority.03:36 Jessica highlights The Rose’s patient navigation program and asks Angie howshe views its importance and future.04:11 Angie calls navigation one of The Rose’s most important services, connects it toher own experience hearing a diagnosis about her child, and underscores howoverwhelming cancer can be even for people already working in healthcare.06:00 Angie talks about the emotional load on patients and families and why having askilled, compassionate navigator alongside them can change the experience oftreatment.07:15 Jessica and Angie touch briefly on funder conversations, the need to explain thatsupport goes far beyond “just a mammogram,” and how navigation, follow‑up, andsystem gaps factor into funding requests.09:30 Angie closes by returning to her core goal: protecting access and quality for everywoman The Rose serves while steering the organization safely through shiftingreimbursement and rural need.See omnystudio.com/listener for privacy information.

Julie Yoo sits down with Dr. Suchi Saria, founder and CEO of Bayesian Health, to discuss the current state of clinical AI and what it takes to deploy AI systems in real-world healthcare settings. While much of the recent attention around AI has focused on copilots, chatbots, and administrative workflows, Saria argues that the greatest opportunity lies in helping clinicians make better decisions at the point of care. She explains how Bayesian Health's clinical intelligence platform continuously analyzes multimodal patient data to identify signs of deterioration, sepsis, and other high-risk conditions before they become medical emergencies. The conversation explores FDA approval, reimbursement, clinician trust, AI governance, hospital workflows, and why healthcare requires a higher standard of evidence than most software categories. Along the way, Saria shares lessons from bringing AI into clinical practice, the future of proactive medicine, and why the next era of healthcare may be defined by continuous intelligence rather than reactive care.   Resources: Follow Suchi Saria on X: https://x.com/suchisaria Follow Julie Yoo on X: https://x.com/julieyoo   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Medsider Radio, we sat down with Dr. Sudhir Srivastava, founder, chairman, and CEO of SS Innovations (Nasdaq: SSII). The company's SSi Mantra surgical robotic system supports a variety of surgical robotic procedures, including cardiac surgery. Sudhir brings more than three decades of experience in minimally invasive and robotic cardiac interventions, having served as Director of Robotic Cardiac Surgery at the University of Chicago and founder of the International College of Robotic Surgery. A pioneer in the field, Sudhir has performed more than 1,400 robotic procedures, including over 750 beating-heart totally endoscopic coronary artery bypass (TECAB) surgeries.In this interview, Sudhir discusses what it takes to democratize robotic surgery beyond affordability, how SS Innovations built teleproctoring, telesurgery, and the supporting infrastructure for its robotic platform, and his milestone-based approach to financing a capital-intensive medtech company. Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Sudhir Srivastava, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:01) - Sudhir's journey from performing the world's first beating-heart robotic bypass to founding SS Innovations (07:14) - The 22-year-old patient who became the catalyst for Sudhir's affordable robotic surgery platform (08:59) - Building Mantra 3 from the ground up in just five months (12:14) - Inside the engineering process that eliminated months of costly iteration (16:20) - The question that shaped SS Innovations: "How do you democratize access?" (27:10) - From one office to performing 24 telesurgeries in 12 hours across India (29:29) - How a mobile training bus became part of Sudhir's answer to make robotic surgery accessible (33:49) - Lessons from commercializing a surgical robotics platform across developing markets (39:43) - Starting with just $5 million: Sudhir's milestone-based approach to fundraising

Healthcare providers are losing valuable time and revenue navigating an outdated insurance system, but what if artificial intelligence could change everything?In this episode of TechTalk Healthcare, Brad Cost and Dr. Jay Greenstein explore how AI could completely transform healthcare reimbursement, insurance claims processing, fraud detection, and provider payments.Together they discuss why insurance companies continue relying on decades-old systems, how AI could approve claims in milliseconds, and why providers deserve faster, fairer reimbursement.They also dive into the role of government regulation, insurance competition, real-time adjudication, and how data transparency can reshape the future of healthcare.Whether you're a chiropractor, healthcare executive, practice owner, revenue cycle professional, or simply interested in AI's impact on healthcare, this episode offers a thought-provoking look at where the industry is headed.You'll learn:How AI can automate insurance claims processingWhy providers wait weeks (or months) to get paidThe future of real-time claim adjudicationHow AI can reduce healthcare fraudWhy healthcare reimbursement needs reformHow data sharing could strengthen provider advocacyThe role of AI in improving patient access to care

Join Angela Graham BSN, RN, CWOCN Ostomy Coloplast Clinical Specialist and Kelly Seegar MPH, Coloplast Senior Manager Payor Relations, as they introduce the TEAM* model. In this first episode of a three-part series, they break down the TEAM MODEL 101 - exploring what it means clinically and financially. Learn how this payment model is redefining accountability for quality care after a major bowel procedure, and how optimizing the ostomy patient pathway can improve outcomes and help meet ostomy surgery targets.   This episode is ideal for healthcare professionals looking to enhance their ostomy patient pathway and ensure their facilities deliver the best possible patient outcomes while meeting evolving care standards. *Transforming Episode Accountability ModelReimbursement Disclaimer: Coloplast Corp. provides this information for convenience and your general reference only. It does not constitute legal advice or a recommendation regarding clinical practice. Reimbursement, coverage and payment policies can vary from one insurer and region to another and is subject to change without notice. The provider has the responsibility to determine medical necessity and to submit appropriate codes and charges for care provided. Coloplast does not guarantee coverage or payment of products and Coloplast makes no guarantee that the use of this information will prevent differences of opinion or disputes with Medicare, insurers, or other payers as to the correct form of billing or the amount that will be paid. This information is provided for your general information only and is not intended to replace any advice you receive from your own internal or external insurance coverage consultants, reimbursement specialists or legal counsel. Additional resources: ·         Supporting Clinicins in Delivering Coordinated, High-quality Ostomy Care Under the TEAM Model, Article by Kelly Seeger, MPH·         Read more about the TEAM model: TEAM (Transforming Episode Accountability Model) | CMS ·         Learn how to enroll your ostomy patients into the Coloplast Care program: www.coloplastcareconnect.us ·         Visit www.coloplast.professional.us for more offerings! 

In this episode of Medsider Radio, we sat down with Aditya Rajagopal, co-founder and CEO of Esperto Medical.Esperto is a Caltech spin-out utilizing compressed sensing technology with ultrasound to continuously and non-invasively measure blood pressure.Before Esperto, Aditya co-founded ChromaCode, a molecular diagnostics company, and was a researcher at Google[x], where he worked on novel medical imaging methods. Aditya also serves as part-time faculty at Caltech and USC, and holds BS, MS, and PhD degrees in Electrical Engineering from Caltech. In this interview, Aditya discusses why great science doesn't necessarily make great companies, what it takes to win as a fast-follower in medtech, and how to sequence a platform technology without spreading resources too thin.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Aditya Rajagopal, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(02:44) - Aditya's journey from Caltech and Google to tackling one of medicine's hardest engineering problems at Esperto (05:17) - How Esperto is trying to solve a 50-year-old problem: continuous blood pressure monitoring without an arterial catheter (07:17) - Why Esperto was okay with being a fast-follower in an established market instead of creating a new one (16:12) - "Great science doesn't necessarily make great companies" and other lessons Aditya learned at ChromaCode (24:02) - Three hurdles every medical device must clear before clinicians will actually adopt it (27:44) - How Aditya determines whether a technical problem actually has a "there there" (37:51) - Esperto's pitch strategy and how it raised from a position of strength (43:18) - What first-time founders often misunderstand about how venture capital actually works

Another conversation with Dr. Brian Gantwerker Find the video of this conversation at https://youtu.be/Bsyg_f7HoCw

In this episode of Medsider Radio, we sat down with Eric Kau, co-founder and CEO of Climatic.Climatic is commercializing L Max, a daily inhaled system that proactively supports lung function.Before Climatic, Eric served as COO of Seed Health and was part of the foundational team at Chewy. Earlier in his career, Eric held growth and operational leadership roles across consumer, wellness, and e-commerce businesses, including Amazon, BoxyCharm, Target, and Best Buy. In this interview, Eric discusses what it takes to build a consumer category that doesn't yet exist, how Climatic approached clinical validation and consumer education simultaneously, and how early user behavior helped identify the company's strongest initial customer cohorts.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Eric Kau, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(02:49) - Eric's path through Amazon, Chewy, Seed, and the consumer health experiences that led to Climatic (05:49) - Why Climatic is treating lung health like hydration, sleep, or nutrition (11:47) - How Climatic rapidly iterated on formulas, delivery systems, and prototypes to launch a product for a new category in under 2 years (14:56) - Climatic's approach to product design, which is built around gym bags, vanities, and existing wellness routines (19:59) - How early users shaped both Climatic's clinical strategy and its go-to-market focus on endurance athletes and biohackers (23:56) - Why Climatic spent more time teaching consumers about lung health than selling the product itself (34:07) - What investors needed to believe before funding a category that didn't yet exist (40:27) - How Climatic built a 15,000-person waitlist through Strava run clubs instead of paid ads

Ask a burned-out pelvic therapist what's draining them and they'll usually say the same thing: it's a lot. The emotional weight of the work, the intimacy of the specialty, the complexity of the cases.But that's not what's actually breaking providers.Pelvic therapists who love their patients are burning out anyway — because the system they work inside was never designed to sustain them. Documentation that bleeds into evenings. Reimbursement rates that haven't kept pace with inflation in a decade. Visit lengths decided by insurance instead of clinical need. And no business training to help them see the exit before they hit the wall.In this episode, Kelly breaks down the real structural drivers of burnout in pelvic health — the ones that have nothing to do with your caseload and everything to do with the model you inherited. She covers the documentation load nobody warned you about in school, the autonomy gap that comes with insurance dependency, and why this is a practice design problem — not a mindset problem, not a resilience problem, and not a you problem.She also covers what the providers who escaped burnout actually did differently. Not the ones who took a vacation and came back to the same broken model. The ones who restructured and stayed.By the end of this episode, you'll know exactly what broke — and where to start fixing it.KEY TAKEAWAYSPelvic therapist burnout is structural, not personal — it's a model problem built into the system before you ever graduatedDocumentation load, reimbursement erosion, and the autonomy gap are the three real drivers — not patient volume or emotional laborThe providers who escaped burnout didn't work less — they rebuilt the model that was consuming them

This week, “Marketplace Morning Report” host Kimberly Adams has been in Thomasville, Alabama as part of our series examining the economic challenges facing rural health care. This morning, we'll look at how low wages in Alabama can mean low Medicare reimbursement rates — shaping how much doctors and nurses get paid, and how much money hospitals and clinics can make. But first, we'll cover how solar power use in the U.S. is hitting new milestones amid energy price fluctuations.

This week, “Marketplace Morning Report” host Kimberly Adams has been in Thomasville, Alabama as part of our series examining the economic challenges facing rural health care. This morning, we'll look at how low wages in Alabama can mean low Medicare reimbursement rates — shaping how much doctors and nurses get paid, and how much money hospitals and clinics can make. But first, we'll cover how solar power use in the U.S. is hitting new milestones amid energy price fluctuations.